Foghorn reports Q2 2026 results, FHD-909 trial on track with Lilly

Foghorn Therapeutics Inc. issued its second quarter 2026 financial and corporate update on August 6, 2026, alongside its 10-Q filing for the period ended June 30, 2026.

The company's lead program, FHD-909 is a first-in-class oral SMARCA2 selective inhibitor that has demonstrated in preclinical studies to have high selectivity over its closely-related paralog SMARCA4¹. Enrollment in the first-in-human Phase 1 multi-center trial of FHD-909 is progressing well, with the trial in patients with NSCLC as the primary target population on track, following the dosing of the first patient in October 2024.¹ Pending successful Phase 1 dose escalation results, Foghorn and Lilly anticipate evaluating FHD-909 in combination studies in NSCLC with pembrolizumab.¹

On the pipeline side, Foghorn is targeting an IND for its Selective EP300 degrader program in 2027, with a focus in multiple myeloma and diffuse large b-cell lymphoma.¹ Separately, the CBPd-171 timeline has been delayed due to an unexpected operational issue at a third-party contract research organization supporting the in vivo animal models, and the company said it will provide updated guidance once available.¹ The company is also advancing a novel oral small molecule in immunology and inflammation, targeting an IND in 2027.¹

Financially, collaboration revenue was $16.1 million for the three months ended June 30, 2026, compared to $7.6 million a year earlier, driven largely by a $14.2 million cumulative catch-up adjustment tied to the scheduled expiration of the Lilly research term in December 2026.¹ Net loss was $7.2 million for the quarter, compared to a net loss of $17.9 million in the same period of 2025.¹ As of June 30, 2026, the company had $167.6 million in cash, cash equivalents, and marketable securities, providing cash runway into the first half of 2028.¹